EGFR and non-small cell lung carcinoma: If clinically meaningful efficacy results are observed and the primary endpoint is achieved, together with an acceptable safety and tolerability profile, findings from this study would demonstrate strong evidence of a new standard for first-line treatment of advanced NSCLC patients harboring activating EGFR mutations.